메뉴 건너뛰기




Volumn 12, Issue 2, 2013, Pages 73-85

Targeted Therapy for Metastatic Colorectal Cancer: Role of Aflibercept

Author keywords

aflibercept; Antiangiogenesis; Metastatic colorectal cancer (mCRC); Placental growth factor; VEGF A; VEGF B

Indexed keywords

AFLIBERCEPT; ALANINE AMINOTRANSFERASE; ANGIOPOIETIN; BEVACIZUMAB; CETUXIMAB; DOCETAXEL; DOXORUBICIN; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IRINOTECAN; OXALIPLATIN; PANITUMUMAB; PLACENTAL GROWTH FACTOR; TYROSINE KINASE RECEPTOR; VASCULOTROPIN; VASCULOTROPIN A; VASCULOTROPIN B; VASCULOTROPIN C; VASCULOTROPIN D; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3;

EID: 84876871687     PISSN: 15330028     EISSN: 19380674     Source Type: Journal    
DOI: 10.1016/j.clcc.2012.08.001     Document Type: Review
Times cited : (36)

References (93)
  • 2
    • 0003964361 scopus 로고    scopus 로고
    • American Cancer Society American Cancer Society Atlanta Accessed: January 1, 2012
    • American Cancer Society Cancer facts and figures 2012 2012 American Cancer Society Atlanta http://www.cancer.org/Research/CancerFactsFigures/index Accessed: January 1, 2012
    • (2012) Cancer Facts and Figures 2012
  • 4
    • 84859416222 scopus 로고    scopus 로고
    • Trends in colorectal cancer incidence rates in the United States by tumor location and stage, 1992-2008
    • R.L. Siegel, E.M. Ward, A. Jemal Trends in colorectal cancer incidence rates in the United States by tumor location and stage, 1992-2008 Cancer Epidemiol Biomarkers Prev 21 2012 411 416
    • (2012) Cancer Epidemiol Biomarkers Prev , vol.21 , pp. 411-416
    • Siegel, R.L.1    Ward, E.M.2    Jemal, A.3
  • 5
    • 80052965666 scopus 로고    scopus 로고
    • Is it time to lower the recommended screening age for colorectal cancer?
    • D.M. Davis, J.E. Marcet, J.C. Frattini Is it time to lower the recommended screening age for colorectal cancer? J Am Coll Surg 213 2011 352 361
    • (2011) J Am Coll Surg , vol.213 , pp. 352-361
    • Davis, D.M.1    Marcet, J.E.2    Frattini, J.C.3
  • 6
    • 78649392125 scopus 로고    scopus 로고
    • The challenge of metastatic colorectal cancer
    • E.U. Cidón The challenge of metastatic colorectal cancer Clin Med Insights Oncol 4 2010 55 60
    • (2010) Clin Med Insights Oncol , vol.4 , pp. 55-60
    • Cidón, E.U.1
  • 7
    • 80052758962 scopus 로고    scopus 로고
    • Characterizing medical care by disease phase in metastatic colorectal cancer
    • X. Song, Z. Zhao, B. Barber Characterizing medical care by disease phase in metastatic colorectal cancer J Oncol Pract 7 2011 25S 30S
    • (2011) J Oncol Pract , vol.7
    • Song, X.1    Zhao, Z.2    Barber, B.3
  • 8
    • 67650315187 scopus 로고    scopus 로고
    • Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial
    • T. André, C. Boni, M. Navarro Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial J Clin Oncol 27 2009 3109 3116
    • (2009) J Clin Oncol , vol.27 , pp. 3109-3116
    • André, T.1    Boni, C.2    Navarro, M.3
  • 9
    • 0015008620 scopus 로고
    • Isolation of a tumor factor responsible for angiogenesis
    • J. Folkman, E. Merler, C. Abernathy Isolation of a tumor factor responsible for angiogenesis J Exp Med 133 1971 275 288
    • (1971) J Exp Med , vol.133 , pp. 275-288
    • Folkman, J.1    Merler, E.2    Abernathy, C.3
  • 12
    • 0036984640 scopus 로고    scopus 로고
    • Role of angiogenesis in tumor growth and metastasis
    • J. Folkman Role of angiogenesis in tumor growth and metastasis Semin Oncol 29 suppl 16 2002 15 18
    • (2002) Semin Oncol , vol.29 , Issue.SUPPL. 16 , pp. 15-18
    • Folkman, J.1
  • 13
    • 0141988568 scopus 로고    scopus 로고
    • Fundamental concepts of the angiogenic process
    • DOI 10.2174/1566524033479465
    • J. Folkman Fundamental concepts of the angiogenic process Curr Mol Med 3 2003 643 651 (Pubitemid 37236406)
    • (2003) Current Molecular Medicine , vol.3 , Issue.7 , pp. 643-651
    • Folkman, J.1
  • 14
    • 77953988924 scopus 로고    scopus 로고
    • Targeting the tumour vasculature: Insights from physiological angiogenesis
    • A.S. Chung, J. Lee, N. Ferrara Targeting the tumour vasculature: insights from physiological angiogenesis Nat Rev Cancer 10 2010 505 514
    • (2010) Nat Rev Cancer , vol.10 , pp. 505-514
    • Chung, A.S.1    Lee, J.2    Ferrara, N.3
  • 15
    • 47949089077 scopus 로고    scopus 로고
    • VEGF targeted therapy: Mechanisms of anti-tumour therapy
    • L.M. Ellis, D.J. Hicklin VEGF targeted therapy: mechanisms of anti-tumour therapy Natl Rev 8 2008 579 591
    • (2008) Natl Rev , vol.8 , pp. 579-591
    • Ellis, L.M.1    Hicklin, D.J.2
  • 16
    • 12344312042 scopus 로고    scopus 로고
    • Cellular abnormalities of blood vessels as targets in cancer
    • DOI 10.1016/j.gde.2004.12.005, PII S0959437X04001911, Oncogenes and Cell Proliferation
    • P. Baluk, H. Hashizume, D.M. McDonald Cellular abnormalities of blood vessels as targets in cancer Curr Opin Genet Dev 15 2005 102 111 (Pubitemid 40127638)
    • (2005) Current Opinion in Genetics and Development , vol.15 , Issue.1 , pp. 102-111
    • Baluk, P.1    Hashizume, H.2    McDonald, D.M.3
  • 17
    • 77950279550 scopus 로고    scopus 로고
    • Tumor microvasculature and microenvironment: Novel insights through intravital imaging in pre-clinical models
    • D. Fukumura, D.G. Duda, L.L. Munn Tumor microvasculature and microenvironment: novel insights through intravital imaging in pre-clinical models Microcirculation 17 2010 206 225
    • (2010) Microcirculation , vol.17 , pp. 206-225
    • Fukumura, D.1    Duda, D.G.2    Munn, L.L.3
  • 18
    • 30744479430 scopus 로고    scopus 로고
    • Angiogenesis in life, disease and medicine
    • DOI 10.1038/nature04478, PII NATURE04478
    • P. Carmeliet Angiogenesis in life, disease and medicine Nature 438 2005 932 936 (Pubitemid 43093958)
    • (2005) Nature , vol.438 , Issue.7070 , pp. 932-936
    • Carmeliet, P.1
  • 19
    • 2942590261 scopus 로고    scopus 로고
    • Vascular endothelial growth factor as a target for anticancer therapy
    • DOI 10.1634/theoncologist.9-suppl-1-2
    • N. Ferrara Vascular endothelial growth factor as a target for anticancer therapy Oncologist 9 suppl 1 2004 2 10 (Pubitemid 38747842)
    • (2004) Oncologist , vol.9 , Issue.SUPPL.. 1 , pp. 2-10
    • Ferrara, N.1
  • 20
    • 30744449235 scopus 로고    scopus 로고
    • Angiogenesis as a therapeutic target
    • DOI 10.1038/nature04483, PII NATURE04483
    • N. Ferrara, R.S. Kerbel Angiogenesis as a therapeutic target Nature 438 2005 967 974 (Pubitemid 43093963)
    • (2005) Nature , vol.438 , Issue.7070 , pp. 967-974
    • Ferrara, N.1    Kerbel, R.S.2
  • 21
    • 70450175957 scopus 로고    scopus 로고
    • Targeting angiogenesis: Progress with anti-VEGF treatment with large molecules
    • A. Grothey, E. Galanis Targeting angiogenesis: progress with anti-VEGF treatment with large molecules Nat Rev Clin Oncol 6 2009 507 518
    • (2009) Nat Rev Clin Oncol , vol.6 , pp. 507-518
    • Grothey, A.1    Galanis, E.2
  • 22
    • 56749174211 scopus 로고    scopus 로고
    • FLT1 and its ligands VEGFB and PlGF: Drug targets for anti-angiogenic therapy?
    • C. Fischer, M. Mazzone, B. Jonckx FLT1 and its ligands VEGFB and PlGF: drug targets for anti-angiogenic therapy? Nat Rev Cancer 8 2008 942 956
    • (2008) Nat Rev Cancer , vol.8 , pp. 942-956
    • Fischer, C.1    Mazzone, M.2    Jonckx, B.3
  • 23
    • 0033047875 scopus 로고    scopus 로고
    • VEGFs, receptors and angiogenesis
    • DOI 10.1006/scbi.1998.0091
    • T. Veikkola, K. Alitalo VEGFs, receptors and angiogenesis Semin Cancer Biol 9 1999 211 220 (Pubitemid 29273837)
    • (1999) Seminars in Cancer Biology , vol.9 , Issue.3 , pp. 211-220
    • Veikkola, T.1    Alitalo, K.2
  • 24
    • 65349186800 scopus 로고    scopus 로고
    • Aflibercept (AVE0005): An alternative strategy for inhibiting tumour angiogenesis by vascular endothelial growth factors
    • Q.S. Chu Aflibercept (AVE0005): an alternative strategy for inhibiting tumour angiogenesis by vascular endothelial growth factors Expert Opin Biol Ther 9 2009 263 271
    • (2009) Expert Opin Biol Ther , vol.9 , pp. 263-271
    • Chu, Q.S.1
  • 25
    • 58149190795 scopus 로고    scopus 로고
    • Pathways mediating resistance to vascular endothelial growth factor-targeted therapy
    • L.M. Ellis, D.J. Hicklin Pathways mediating resistance to vascular endothelial growth factor-targeted therapy Clin Cancer Res 14 2008 6371 6375
    • (2008) Clin Cancer Res , vol.14 , pp. 6371-6375
    • Ellis, L.M.1    Hicklin, D.J.2
  • 26
    • 4143136640 scopus 로고    scopus 로고
    • Vascular endothelial growth factor: Basic science and clinical progress
    • DOI 10.1210/er.2003-0027
    • N. Ferrara Vascular endothelial growth factor: basic science and clinical progress Endocr Rev 25 2004 581 611 (Pubitemid 39099316)
    • (2004) Endocrine Reviews , vol.25 , Issue.4 , pp. 581-611
    • Ferrara, N.1
  • 27
    • 0032907687 scopus 로고    scopus 로고
    • Vascular endothelial growth factor (VEGF) and its receptors
    • G. Neufeld, T. Cohen, S. Gengrinovitch Vascular endothelial growth factor (VEGF) and its receptors FASEB J 13 1999 9 22 (Pubitemid 29038270)
    • (1999) FASEB Journal , vol.13 , Issue.1 , pp. 9-22
    • Neufeld, G.1    Cohen, T.2    Gengrinovitch, S.3    Poltorak, Z.4
  • 28
    • 0028870050 scopus 로고
    • Induction of vascular endothelial growth factor expression by hypoxia and by glucose deficiency in multicell spheroids: Implications for tumor angiogenesis
    • D. Shweiki, M. Neeman, A. Itin Induction of vascular endothelial growth factor expression by hypoxia and by glucose deficiency in multicell spheroids: implications for tumor angiogenesis Proc Natl Acad Sci U S A 92 1995 768 772
    • (1995) Proc Natl Acad Sci U S A , vol.92 , pp. 768-772
    • Shweiki, D.1    Neeman, M.2    Itin, A.3
  • 29
    • 79960037492 scopus 로고    scopus 로고
    • Tyrosine kinase receptor Flt/VEGFR family: Its characterization related to angiogenesis and cancer
    • M. Shibuya Tyrosine kinase receptor Flt/VEGFR family: its characterization related to angiogenesis and cancer Genes Cancer 1 2010 1119 1123
    • (2010) Genes Cancer , vol.1 , pp. 1119-1123
    • Shibuya, M.1
  • 31
    • 0026702970 scopus 로고
    • Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor
    • B.I. Terman, M. Dougher-Vermazen, M.E. Carrion Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor Biochem Biophys Res Commun 187 1992 1579 1586
    • (1992) Biochem Biophys Res Commun , vol.187 , pp. 1579-1586
    • Terman, B.I.1    Dougher-Vermazen, M.2    Carrion, M.E.3
  • 32
    • 0029006696 scopus 로고
    • Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice
    • F. Shalaby, J. Rossant, T.P. Yamaguchi Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice Nature 376 1995 62 66
    • (1995) Nature , vol.376 , pp. 62-66
    • Shalaby, F.1    Rossant, J.2    Yamaguchi, T.P.3
  • 33
    • 70350445902 scopus 로고    scopus 로고
    • VEGF-B: A survival, or an angiogenic factor?
    • X. Li, C. Lee, Z. Tang VEGF-B: a survival, or an angiogenic factor? Cell Adh Migr 3 2009 322 327
    • (2009) Cell Adh Migr , vol.3 , pp. 322-327
    • Li, X.1    Lee, C.2    Tang, Z.3
  • 36
    • 65549139264 scopus 로고    scopus 로고
    • VEGF-B is dispensable for blood vessel growth but critical for their survival, and VEGF-B targeting inhibits pathological angiogenesis
    • F. Zhang, Z. Tang, X. Hou VEGF-B is dispensable for blood vessel growth but critical for their survival, and VEGF-B targeting inhibits pathological angiogenesis Proc Natl Acad Sci U S A 106 2009 6152 6157
    • (2009) Proc Natl Acad Sci U S A , vol.106 , pp. 6152-6157
    • Zhang, F.1    Tang, Z.2    Hou, X.3
  • 37
    • 0142120350 scopus 로고    scopus 로고
    • Evidence of a novel isoform of placenta growth factor (P1GF-4) expressed in human trophoblast and endothelial cells
    • DOI 10.1016/S0165-0378(03)00082-2
    • W. Yang, H. Ahn, M. Hinrichs Evidence of a novel isoform of placenta growth factor (PlGF-4) expressed in human trophoblast and endothelial cells J Reprod Immunol 60 2003 53 60 (Pubitemid 37272295)
    • (2003) Journal of Reproductive Immunology , vol.60 , Issue.1 , pp. 53-60
    • Yang, W.1    Ahn, H.2    Hinrichs, M.3    Torry, R.J.4    Torry, D.S.5
  • 38
    • 0030050025 scopus 로고    scopus 로고
    • Flt-1 but not KDR/Flk-1 tyrosine kinase is a receptor for placenta growth factor, which is related to vascular endothelial growth factor
    • A. Sawano, T. Takahashi, S. Yamaguchi Flt-1 but not KDR/Flk-1 tyrosine kinase is a receptor for placenta growth factor, which is related to vascular endothelial growth factor Cell Growth Differ 7 1996 213 221 (Pubitemid 26049830)
    • (1996) Cell Growth and Differentiation , vol.7 , Issue.2 , pp. 213-221
    • Sawano, A.1    Takahashi, T.2    Yamaguchi, S.3    Aonuma, M.4    Shibuya, M.5
  • 39
    • 69549116791 scopus 로고    scopus 로고
    • PGF isoforms, PLGF-1 and PGF-2, in colorectal cancer and the prognostic significance
    • A. Escudero-Esparza, T.A. Martin, M.L. Davies PGF isoforms, PLGF-1 and PGF-2, in colorectal cancer and the prognostic significance Cancer Genomics Proteomics 6 2009 239 246
    • (2009) Cancer Genomics Proteomics , vol.6 , pp. 239-246
    • Escudero-Esparza, A.1    Martin, T.A.2    Davies, M.L.3
  • 41
    • 79960111080 scopus 로고    scopus 로고
    • Phase II study of aflibercept in recurrent malignant glioma: A North American Brain Tumor Consortium study
    • J.F. De Groot, K.R. Lamborn, S.M. Chang Phase II study of aflibercept in recurrent malignant glioma: a North American Brain Tumor Consortium study J Clin Oncol 29 2011 2689 2695
    • (2011) J Clin Oncol , vol.29 , pp. 2689-2695
    • De Groot, J.F.1    Lamborn, K.R.2    Chang, S.M.3
  • 42
    • 18744405611 scopus 로고    scopus 로고
    • Genentech Inc South San Francisco, CA
    • Avastin [package insert] 2009 Genentech Inc South San Francisco, CA
    • (2009) Avastin [Package Insert]
  • 43
    • 84860825824 scopus 로고    scopus 로고
    • Imclone LLC Branchburg, NJ
    • Erbitux [package insert] 2012 Imclone LLC Branchburg, NJ
    • (2012) Erbitux [Package Insert]
  • 44
    • 84860809709 scopus 로고    scopus 로고
    • Amgen Inc Thousand Oaks, CA
    • Vectibix [package insert] 2011 Amgen Inc Thousand Oaks, CA
    • (2011) Vectibix [Package Insert]
  • 46
    • 77955887676 scopus 로고    scopus 로고
    • Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: Phase III trial of the cancer and Leukemia Group B (CALGB 80303)
    • H.L. Kindler, D. Niedzwiecki, D. Hollis Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the cancer and Leukemia Group B (CALGB 80303) J Clin Oncol 28 2010 3617 3622
    • (2010) J Clin Oncol , vol.28 , pp. 3617-3622
    • Kindler, H.L.1    Niedzwiecki, D.2    Hollis, D.3
  • 47
    • 77951296573 scopus 로고    scopus 로고
    • Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer
    • C.H. Barrios, M.C. Liu, S.C. Lee Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer Breast Cancer Res Treat 121 2010 121 131
    • (2010) Breast Cancer Res Treat , vol.121 , pp. 121-131
    • Barrios, C.H.1    Liu, M.C.2    Lee, S.C.3
  • 48
    • 84865243485 scopus 로고    scopus 로고
    • Overcoming resistance to antiangiogenic therapies
    • Epub 2012 Jul 6
    • S. Tejpar, H. Prenen, M. Mazzone Overcoming resistance to antiangiogenic therapies Oncologist 17 2012 1039 1050 Epub 2012 Jul 6
    • (2012) Oncologist , vol.17 , pp. 1039-1050
    • Tejpar, S.1    Prenen, H.2    Mazzone, M.3
  • 49
    • 84863888220 scopus 로고    scopus 로고
    • Combining antiangiogenics to overcome resistance: Rationale and clinical experience
    • V. Moreno Garcia, B. Basu, L.R. Molife Combining antiangiogenics to overcome resistance: rationale and clinical experience Clin Cancer Res 18 2012 3750 3761
    • (2012) Clin Cancer Res , vol.18 , pp. 3750-3761
    • Moreno Garcia, V.1    Basu, B.2    Molife, L.R.3
  • 50
    • 47949099628 scopus 로고    scopus 로고
    • Modes of resistance to anti-angiogenic therapy
    • G. Bergers, D. Hanahan Modes of resistance to anti-angiogenic therapy Nat Rev Cancer 8 2008 592 603
    • (2008) Nat Rev Cancer , vol.8 , pp. 592-603
    • Bergers, G.1    Hanahan, D.2
  • 51
    • 79954451405 scopus 로고    scopus 로고
    • Pharmacodynamic and pharmacogenetic angiogenesis-related markers of first-line FOLFOXIRI plus bevacizumab schedule in metastatic colorectal cancer
    • F. Loupakis, C. Cremolini, A. Fioravanti Pharmacodynamic and pharmacogenetic angiogenesis-related markers of first-line FOLFOXIRI plus bevacizumab schedule in metastatic colorectal cancer Br J Cancer 104 2011 1262 1269
    • (2011) Br J Cancer , vol.104 , pp. 1262-1269
    • Loupakis, F.1    Cremolini, C.2    Fioravanti, A.3
  • 52
    • 79960984152 scopus 로고    scopus 로고
    • Expression of a functional VEGFR-1 in tumor cells is a major determinant of anti-PlGF antibodies efficacy
    • J. Yao, X. Wu, G. Zhuang Expression of a functional VEGFR-1 in tumor cells is a major determinant of anti-PlGF antibodies efficacy Proc Natl Acad Sci U S A 108 2011 11590 11595
    • (2011) Proc Natl Acad Sci U S A , vol.108 , pp. 11590-11595
    • Yao, J.1    Wu, X.2    Zhuang, G.3
  • 54
    • 75749096309 scopus 로고    scopus 로고
    • Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: Efficacy and circulating angiogenic biomarkers associated with therapeutic resistance
    • S. Kopetz, P.M. Hoff, J.S. Morris Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance J Clin Oncol 28 2010 453 459
    • (2010) J Clin Oncol , vol.28 , pp. 453-459
    • Kopetz, S.1    Hoff, P.M.2    Morris, J.S.3
  • 56
    • 74949101370 scopus 로고    scopus 로고
    • Phase 1 study of aflibercept administered subcutaneously to patients with advanced solid tumors
    • W.P. Tew, M. Gordon, J. Murren Phase 1 study of aflibercept administered subcutaneously to patients with advanced solid tumors Clin Cancer Res 16 2010 358 366
    • (2010) Clin Cancer Res , vol.16 , pp. 358-366
    • Tew, W.P.1    Gordon, M.2    Murren, J.3
  • 57
    • 84861382251 scopus 로고    scopus 로고
    • Intravenous (IV) aflibercept versus placebo in combination with irinotecan/5-FU (FOLFIRI) for second-line treatment of metastatic colorectal cancer (mCRC): Results of a multinational phase III trial (EFC10262-VELOUR)
    • June 25 Barcelona, Spain
    • Van Cutsem E, Tabernero J, Lakomy R, et al. Intravenous (IV) aflibercept versus placebo in combination with irinotecan/5-FU (FOLFIRI) for second-line treatment of metastatic colorectal cancer (mCRC): results of a multinational phase III trial (EFC10262-VELOUR). Paper presented at: Congress on Gastrointestinal Cancer. European Society for Medical Oncology (ESMO). June 25, 2011; Barcelona, Spain.
    • (2011) Congress on Gastrointestinal Cancer. European Society for Medical Oncology (ESMO)
    • Van Cutsem, E.1    Tabernero, J.2    Lakomy, R.3
  • 58
    • 77958198446 scopus 로고    scopus 로고
    • Aflibercept (VEGF Trap): One more double-edged sword of anti-VEGF therapy for cancer?
    • K. Jin, Y. Shen, K. He Aflibercept (VEGF Trap): one more double-edged sword of anti-VEGF therapy for cancer? Clin Transl Oncol 12 2010 526 532
    • (2010) Clin Transl Oncol , vol.12 , pp. 526-532
    • Jin, K.1    Shen, Y.2    He, K.3
  • 59
    • 84876832098 scopus 로고    scopus 로고
    • Regeneron Pharmaceuticals, Inc./sanofi-aventis, U.S. LLC Bridgewater, NJ
    • Zaltrap [prescribing information] 2012 Regeneron Pharmaceuticals, Inc./sanofi-aventis, U.S. LLC Bridgewater, NJ
    • (2012) Zaltrap [Prescribing Information]
  • 61
    • 70349330817 scopus 로고    scopus 로고
    • VEGF Trap-eye for the treatment of neovascular age-related macular degeneration
    • J.A. Dixon, S.C. Oliver, J.L. Olson VEGF Trap-eye for the treatment of neovascular age-related macular degeneration Expert Opin Investig Drugs 18 2009 1573 1580
    • (2009) Expert Opin Investig Drugs , vol.18 , pp. 1573-1580
    • Dixon, J.A.1    Oliver, S.C.2    Olson, J.L.3
  • 62
    • 84865129521 scopus 로고    scopus 로고
    • Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab
    • N. Papadopoulos, J. Martin, Q. Ruan Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab Angiogenesis 15 2012 171 185
    • (2012) Angiogenesis , vol.15 , pp. 171-185
    • Papadopoulos, N.1    Martin, J.2    Ruan, Q.3
  • 63
    • 74949119167 scopus 로고    scopus 로고
    • Phase i study of intravenous vascular endothelial growth factor trap, aflibercept, in patients with advanced solid tumors
    • A.C. Lockhart, M.L. Rothenberg, J. Dupont Phase I study of intravenous vascular endothelial growth factor trap, aflibercept, in patients with advanced solid tumors J Clin Oncol 28 2010 207 214
    • (2010) J Clin Oncol , vol.28 , pp. 207-214
    • Lockhart, A.C.1    Rothenberg, M.L.2    Dupont, J.3
  • 66
    • 78650378957 scopus 로고    scopus 로고
    • Effect of VEGF and VEGF Trap on vascular endothelial cell signaling in tumors
    • W. Lassoued, D. Murphy, J. Tsai Effect of VEGF and VEGF Trap on vascular endothelial cell signaling in tumors Cancer Biol Ther 10 2011 1326 1333
    • (2011) Cancer Biol Ther , vol.10 , pp. 1326-1333
    • Lassoued, W.1    Murphy, D.2    Tsai, J.3
  • 67
    • 84876850852 scopus 로고    scopus 로고
    • Synergistic activity of aflibercept (VEGF Trap) in combination with 5-fluorouracil and irinotecan in preclinical tumor models
    • San Francisco, CA, October 2007:A13
    • M. Chiron, P. Vrignaud, P. Lejeune Synergistic activity of aflibercept (VEGF Trap) in combination with 5-fluorouracil and irinotecan in preclinical tumor models AACR Meeting Abstracts 2007 San Francisco, CA, October 2007:A13
    • (2007) AACR Meeting Abstracts
    • Chiron, M.1    Vrignaud, P.2    Lejeune, P.3
  • 68
    • 84876873394 scopus 로고    scopus 로고
    • Combination of the antiangiogenic agent aflibercept (VEGF Trap) with docetaxel and gemcitabine results in greater antitumor activity in tumor-bearing mice
    • April 12-16 San Diego, CA. Abstract 1107
    • Lejeune P, Chiron M, Moigne RL, et al. Combination of the antiangiogenic agent aflibercept (VEGF Trap) with docetaxel and gemcitabine results in greater antitumor activity in tumor-bearing mice. Presented at: the American Association for Cancer Research (AACR) Annual Meeting, April 12-16, 2008; San Diego, CA. Abstract 1107.
    • (2008) American Association for Cancer Research (AACR) Annual Meeting
    • Lejeune, P.1    Chiron, M.2    Moigne, R.L.3
  • 69
    • 85019781927 scopus 로고    scopus 로고
    • Combination of aflibercept (VEGF Trap) and docetaxel produces increased antitumor effects associated with enhanced changes to tumor vasculature
    • April 17-21 Washington, DC. Abstract 5427
    • Abrahams C, Li B, Parveen A, et al. Combination of aflibercept (VEGF Trap) and docetaxel produces increased antitumor effects associated with enhanced changes to tumor vasculature. Presented at: the American Association for Cancer Research (AACR). Annual Meeting, April 17-21, 2010; Washington, DC. Abstract 5427.
    • (2010) The American Association for Cancer Research (AACR). Annual Meeting
    • Abrahams, C.1    Li, B.2    Parveen, A.3
  • 70
    • 77958061434 scopus 로고    scopus 로고
    • Aflibercept exerts antivascular effects and enhances levels of anthracycline chemotherapy in vivo in human acute myeloid leukemia models
    • D. Lal, J.A. Park, K. Demock Aflibercept exerts antivascular effects and enhances levels of anthracycline chemotherapy in vivo in human acute myeloid leukemia models Mol Cancer Ther 9 2010 2737 2751
    • (2010) Mol Cancer Ther , vol.9 , pp. 2737-2751
    • Lal, D.1    Park, J.A.2    Demock, K.3
  • 71
    • 69249228874 scopus 로고    scopus 로고
    • A phase i dose escalation and pharmacokinetic (PK) study of intravenous (iv) aflibercept (VEGF Trap) plus FOLFOX4 in patients (pts) with advanced solid tumors: Preliminary results
    • abstract:3556 Accessed: September 15, 2012
    • S.A. Limentani, R. Just, A. Purdham A phase I dose escalation and pharmacokinetic (PK) study of intravenous (iv) aflibercept (VEGF Trap) plus FOLFOX4 in patients (pts) with advanced solid tumors: preliminary results J Clin Oncol 26 suppl 2008 abstract:3556 www.asco.org Accessed: September 15, 2012
    • (2008) J Clin Oncol , vol.26 , Issue.SUPPL.
    • Limentani, S.A.1    Just, R.2    Purdham, A.3
  • 72
    • 77953674924 scopus 로고    scopus 로고
    • A phase i dose escalation (DE) and pharmacokinetics (PK) study of intravenous (iv) aflibercept (VEGF Trap) plus irinotecan, 5-fluorouracil, and leucovorin (I-LV5-FU2) in patients with advanced solid tumors (STs)
    • abstract:3557 Accessed September 15, 2012
    • O. Rixe, C. Verslype, D. Khayat A phase I dose escalation (DE) and pharmacokinetics (PK) study of intravenous (iv) aflibercept (VEGF Trap) plus irinotecan, 5-fluorouracil, and leucovorin (I-LV5-FU2) in patients with advanced solid tumors (STs) J Clin Oncol 26 suppl 2008 abstract:3557 www.asco.org Accessed September 15, 2012
    • (2008) J Clin Oncol , vol.26 , Issue.SUPPL.
    • Rixe, O.1    Verslype, C.2    Khayat, D.3
  • 73
    • 84858193113 scopus 로고    scopus 로고
    • Phase i dose-escalation study of intravenous aflibercept in combination with docetaxel in patients with advanced solid tumors
    • N. Isambert, G. Freyer, S. Zanetta Phase I dose-escalation study of intravenous aflibercept in combination with docetaxel in patients with advanced solid tumors Clin Cancer Res 18 2012 1743 1750
    • (2012) Clin Cancer Res , vol.18 , pp. 1743-1750
    • Isambert, N.1    Freyer, G.2    Zanetta, S.3
  • 74
    • 77953667091 scopus 로고    scopus 로고
    • A phase i dose escalation and pharmacokinetic (PK) study of intravenous (iv) aflibercept (VEGF Trap) plus docetaxel (D) and cisplatin (C) in patients (pts) with advanced solid tumors: Preliminary results
    • abstract:14539 Accessed: September 15, 2012
    • G. Freyer, P. Fumoleau, B. You A phase I dose escalation and pharmacokinetic (PK) study of intravenous (iv) aflibercept (VEGF Trap) plus docetaxel (D) and cisplatin (C) in patients (pts) with advanced solid tumors: preliminary results J Clin Oncol 26 suppl 2008 abstract:14539 www.asco.org Accessed: September 15, 2012
    • (2008) J Clin Oncol , vol.26 , Issue.SUPPL.
    • Freyer, G.1    Fumoleau, P.2    You, B.3
  • 75
    • 69249228874 scopus 로고    scopus 로고
    • A phase i dose escalation and pharmacokinetic (PK) study of intravenous (iv) aflibercept (VEGF Trap) plus weekly gemcitabine (gem) in patients (pts) with advanced solid tumors: Preliminary results
    • abstract:3558 Accessed: September 15, 2012
    • A. Patnaik, M. Pipas, L. Rosen A phase I dose escalation and pharmacokinetic (PK) study of intravenous (iv) aflibercept (VEGF Trap) plus weekly gemcitabine (gem) in patients (pts) with advanced solid tumors: preliminary results J Clin Oncol 26 suppl 2008 abstract:3558 www.asco.org Accessed: September 15, 2012
    • (2008) J Clin Oncol , vol.26 , Issue.SUPPL.
    • Patnaik, A.1    Pipas, M.2    Rosen, L.3
  • 76
    • 84876824206 scopus 로고    scopus 로고
    • Phase i dose escalation and pharmacokinetics study of intravenous aflibercept plus irinotecan, 5-fluorouracil, and folinic acid (FOLFIRI) in patients with metastatic colorectal cancer
    • abstract:538 Accessed: September 15, 2012
    • K. Yamazaki, T. Yoshino, K. Yamaguchi Phase I dose escalation and pharmacokinetics study of intravenous aflibercept plus irinotecan, 5-fluorouracil, and folinic acid (FOLFIRI) in patients with metastatic colorectal cancer J Clin Oncol 29 suppl 2011 abstract:538 www.asco.org Accessed: September 15, 2012
    • (2011) J Clin Oncol , vol.29 , Issue.SUPPL.
    • Yamazaki, K.1    Yoshino, T.2    Yamaguchi, K.3
  • 77
    • 36849005801 scopus 로고    scopus 로고
    • VEGF-Trap for patients (pts) with recurrent platinum-resistant epithelial ovarian cancer (EOC): Preliminary results of a randomized, multicenter phase II study
    • abstract:5508 Accessed: September 15, 2012
    • W.P. Tew, N. Colombo, I. Ray-Coquard VEGF-Trap for patients (pts) with recurrent platinum-resistant epithelial ovarian cancer (EOC): preliminary results of a randomized, multicenter phase II study J Clin Oncol 25 suppl 2007 abstract:5508 www.asco.org Accessed: September 15, 2012
    • (2007) J Clin Oncol , vol.25 , Issue.SUPPL.
    • Tew, W.P.1    Colombo, N.2    Ray-Coquard, I.3
  • 78
    • 54849433672 scopus 로고    scopus 로고
    • Phase II study of the efficacy and safety of intravenous (IV) AVE0005 (VEGF Trap) given every 2 weeks in patients (Pts) with platinum- and erlotinib-resistant adenocarcinoma of the lung (NSCLA)
    • abstract:7627 Accessed: September 15, 2012
    • E. Massarelli, V.A. Miller, N.B. Leighl Phase II study of the efficacy and safety of intravenous (IV) AVE0005 (VEGF Trap) given every 2 weeks in patients (Pts) with platinum- and erlotinib-resistant adenocarcinoma of the lung (NSCLA) J Clin Oncol 25 suppl 2007 abstract:7627 www.asco.org Accessed: September 15, 2012
    • (2007) J Clin Oncol , vol.25 , Issue.SUPPL.
    • Massarelli, E.1    Miller, V.A.2    Leighl, N.B.3
  • 79
    • 84858336778 scopus 로고    scopus 로고
    • A phase II study of aflibercept in patients with advanced epithelial ovarian cancer and symptomatic malignant ascites
    • N. Colombo, G. Mangili, S. Mammoliti A phase II study of aflibercept in patients with advanced epithelial ovarian cancer and symptomatic malignant ascites Gynecol Oncol 125 2012 42 47
    • (2012) Gynecol Oncol , vol.125 , pp. 42-47
    • Colombo, N.1    Mangili, G.2    Mammoliti, S.3
  • 80
    • 81255185158 scopus 로고    scopus 로고
    • Phase 1-2 study of docetaxel plus aflibercept in patients with recurrent ovarian, primary peritoneal, or fallopian tube cancer
    • R.L. Coleman, L.R. Duska, P.T. Ramirez Phase 1-2 study of docetaxel plus aflibercept in patients with recurrent ovarian, primary peritoneal, or fallopian tube cancer Lancet Oncol 12 2011 1109 1117
    • (2011) Lancet Oncol , vol.12 , pp. 1109-1117
    • Coleman, R.L.1    Duska, L.R.2    Ramirez, P.T.3
  • 81
    • 84856509199 scopus 로고    scopus 로고
    • Intravenous aflibercept for treatment of recurrent symptomatic malignant ascites in patients with advanced ovarian cancer: A phase 2, randomised, double-blind, placebo-controlled study
    • W.H. Gotlieb, F. Amant, S. Advani Intravenous aflibercept for treatment of recurrent symptomatic malignant ascites in patients with advanced ovarian cancer: a phase 2, randomised, double-blind, placebo-controlled study Lancet Oncol 13 2012 154 162
    • (2012) Lancet Oncol , vol.13 , pp. 154-162
    • Gotlieb, W.H.1    Amant, F.2    Advani, S.3
  • 82
    • 55749102152 scopus 로고    scopus 로고
    • Phase II single arm trial of aflibercept in patients with recurrent temozolomide-resistant glioblastoma: NABTC 0601
    • abstract:2020 Accessed: September 15, 2012
    • J.F. De Groot, P.Y. Wen, K. Lamborn Phase II single arm trial of aflibercept in patients with recurrent temozolomide-resistant glioblastoma: NABTC 0601 J Clin Oncol 26 suppl 2008 abstract:2020 www.asco.org Accessed: September 15, 2012
    • (2008) J Clin Oncol , vol.26 , Issue.SUPPL.
    • De Groot, J.F.1    Wen, P.Y.2    Lamborn, K.3
  • 83
    • 67649262706 scopus 로고    scopus 로고
    • Phase II trial of aflibercept (VEGF Trap) in previously treated patients with metastatic colorectal cancer (MCRC): A PMH phase II consortium trial
    • abstract:4027 Accessed: September 15, 2012
    • P. Tang, S.J. Cohen, G.A. Bjarnason Phase II trial of aflibercept (VEGF Trap) in previously treated patients with metastatic colorectal cancer (MCRC): a PMH phase II consortium trial J Clin Oncol 26 suppl 2008 abstract:4027 www.asco.org Accessed: September 15, 2012
    • (2008) J Clin Oncol , vol.26 , Issue.SUPPL.
    • Tang, P.1    Cohen, S.J.2    Bjarnason, G.A.3
  • 84
    • 77957068007 scopus 로고    scopus 로고
    • A phase II study of aflibercept (VEGF Trap) in recurrent or metastatic gynecologic soft-tissue sarcomas: A study of the Princess Margaret Hospital Phase II Consortium
    • abstract 5591 Accessed: September 15, 2012
    • C. Townsley, H. Hirte, P. Hoskins A phase II study of aflibercept (VEGF Trap) in recurrent or metastatic gynecologic soft-tissue sarcomas: a study of the Princess Margaret Hospital Phase II Consortium J Clin Oncol 27 suppl 2009 abstract 5591 www.asco.org Accessed: September 15, 2012
    • (2009) J Clin Oncol , vol.27 , Issue.SUPPL.
    • Townsley, C.1    Hirte, H.2    Hoskins, P.3
  • 85
    • 77950182626 scopus 로고    scopus 로고
    • Phase II study of aflibercept (VEGF Trap) in recurrent inoperable stage III or stage IV melanoma of cutaneous or ocular origin
    • abstract:9028 Accessed: September 15, 2012
    • A.A. Tarhini, S. Christensen, P. Frankel Phase II study of aflibercept (VEGF Trap) in recurrent inoperable stage III or stage IV melanoma of cutaneous or ocular origin J Clin Oncol 27 suppl 2009 abstract:9028 www.asco.org Accessed: September 15, 2012
    • (2009) J Clin Oncol , vol.27 , Issue.SUPPL.
    • Tarhini, A.A.1    Christensen, S.2    Frankel, P.3
  • 86
    • 77957756488 scopus 로고    scopus 로고
    • Phase II study of aflibercept (VEGF-Trap) in patients with recurrent or metastatic urothelial cancer, a California Cancer Consortium trial
    • P. Twardowski, W.M. Stadler, P. Frankel Phase II study of aflibercept (VEGF-Trap) in patients with recurrent or metastatic urothelial cancer, a California Cancer Consortium trial Urology 76 2010 923 926
    • (2010) Urology , vol.76 , pp. 923-926
    • Twardowski, P.1    Stadler, W.M.2    Frankel, P.3
  • 87
    • 77954428008 scopus 로고    scopus 로고
    • A multicenter, phase 2 study of vascular endothelial growth factor trap (Aflibercept) in platinum- and erlotinib-resistant adenocarcinoma of the lung
    • N.B. Leighl, L.E. Raez, B. Besse A multicenter, phase 2 study of vascular endothelial growth factor trap (Aflibercept) in platinum- and erlotinib-resistant adenocarcinoma of the lung J Thorac Oncol 5 2010 1054 1059
    • (2010) J Thorac Oncol , vol.5 , pp. 1054-1059
    • Leighl, N.B.1    Raez, L.E.2    Besse, B.3
  • 88
    • 84858339404 scopus 로고    scopus 로고
    • A phase II study single agent of aflibercept (VEGF Trap) in patients with recurrent or metastatic gynecologic carcinosarcomas and uterine leiomyosarcoma A trial of the Princess Margaret Hospital, Chicago and California cancer phase II consortia
    • H.J. Mackay, R.J. Buckanovich, H. Hirte A phase II study single agent of aflibercept (VEGF Trap) in patients with recurrent or metastatic gynecologic carcinosarcomas and uterine leiomyosarcoma A trial of the Princess Margaret Hospital, Chicago and California cancer phase II consortia Gynecol Oncol 125 2012 136 140
    • (2012) Gynecol Oncol , vol.125 , pp. 136-140
    • Mackay, H.J.1    Buckanovich, R.J.2    Hirte, H.3
  • 89
    • 84861327108 scopus 로고    scopus 로고
    • Results from VELOUR, a phase 3 study of aflibercept versus placebo in combination with FOLFIRI for the treatment of patients with previously treated metastatic colorectal cancer
    • September 23-27 Stockholm, Sweden. Abstract 6LBA
    • Tabernero J, Van Cutsem E, Lakomy R, et al. Results from VELOUR, a phase 3 study of aflibercept versus placebo in combination with FOLFIRI for the treatment of patients with previously treated metastatic colorectal cancer. Paper presented at: 2011 European Multidisciplinary Congress; September 23-27, 2011; Stockholm, Sweden. Abstract 6LBA
    • (2011) 2011 European Multidisciplinary Congress
    • Tabernero, J.1    Van Cutsem, E.2    Lakomy, R.3
  • 90
    • 34248173883 scopus 로고    scopus 로고
    • Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: Results from the Eastern Cooperative Oncology Group Study E3200
    • DOI 10.1200/JCO.2006.09.6305
    • B.J. Giantonio, P.J. Catalano, N.J. Neropol Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200 J Clin Oncol 25 2007 1539 1544 (Pubitemid 46733080)
    • (2007) Journal of Clinical Oncology , vol.25 , Issue.12 , pp. 1539-1544
    • Giantonio, B.J.1    Catalano, P.J.2    Meropol, N.J.3    O'Dwyer, P.J.4    Mitchell, E.P.5    Alberts, S.R.6    Schwartz, M.A.7    Benson III, A.B.8
  • 91
    • 84866152751 scopus 로고    scopus 로고
    • Bevacizumab (BEV) plus chemotherapy (CT) continued beyond first progression in patients with metastatic colorectal cancer (mCRC) previously treated with BEV plus CT: Results of a randomized phase III intergroup study (TML study)
    • abstract CRA3503 Accessed: September 15, 2012
    • D. Arnold, T. Andre, J. Bennouna Bevacizumab (BEV) plus chemotherapy (CT) continued beyond first progression in patients with metastatic colorectal cancer (mCRC) previously treated with BEV plus CT: results of a randomized phase III intergroup study (TML study) J Clin Oncol 30 suppl 2012 abstract CRA3503 www.asco.org Accessed: September 15, 2012
    • (2012) J Clin Oncol , vol.30 , Issue.SUPPL.
    • Arnold, D.1    Andre, T.2    Bennouna, J.3
  • 92
    • 81155126233 scopus 로고    scopus 로고
    • Aflibercept (VEGF-TRAP): The next anti-VEGF drug
    • M.W. Stewart Aflibercept (VEGF-TRAP): the next anti-VEGF drug Inflamm Allergy Drug Targets 10 2011 497 508
    • (2011) Inflamm Allergy Drug Targets , vol.10 , pp. 497-508
    • Stewart, M.W.1
  • 93
    • 77957072191 scopus 로고    scopus 로고
    • Validation of the selected dose of aflibercept (VEGF Trap) plus irinotecan, 5-fluorouracil, and leucovorin (I-LV5FU2) in a phase i clinical trial of patients (pts) with advanced solid tumors (STs): Preliminary results
    • abstract:14540 Accessed: September 15, 2012
    • C. Verslype, J. Spano, E. Van Cusem Validation of the selected dose of aflibercept (VEGF Trap) plus irinotecan, 5-fluorouracil, and leucovorin (I-LV5FU2) in a phase I clinical trial of patients (pts) with advanced solid tumors (STs): preliminary results J Clin Oncol 26 suppl 2008 abstract:14540 www.asco.org Accessed: September 15, 2012
    • (2008) J Clin Oncol , vol.26 , Issue.SUPPL.
    • Verslype, C.1    Spano, J.2    Van Cusem, E.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.